Hims announced it will stop offering a compounded version of Novo Nordisk’s Wegovy following legal threats and regulatory scrutiny. The telehealth company said it “decided to stop offering access” after federal regulators escalated enforcement threats tied to the unapproved formulation. Novo Nordisk and U.S. regulators raised concerns that mass compounding of an approved branded product could undermine safety and innovation. The move follows rapid market demand for GLP‑1 medicines and intensifying scrutiny of unapproved copies of high-profile weight‑loss drugs. The withdrawal underscores growing legal and commercial friction around compounded GLP‑1 products and sets a precedent for how regulators may respond to telehealth companies offering unapproved versions of patented, approved therapies.